相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy
Itay Lotan et al.
CURRENT NEUROPHARMACOLOGY (2021)
Immunological Role of IgG Subclasses
Cecilia Napodano et al.
IMMUNOLOGICAL INVESTIGATIONS (2021)
Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis
Pengcheng Zhang et al.
BONE MARROW TRANSPLANTATION (2020)
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
Yoshiki Takai et al.
BRAIN (2020)
Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options
Mattia Rosso et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
Karissa L. Gable et al.
FRONTIERS IN IMMUNOLOGY (2020)
FcRn, but not Fc γRs, drives maternal-fetal transplacental transport of human IgG antibodies
Sara Borghi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance
Angelina Mimoun et al.
FRONTIERS IN IMMUNOLOGY (2020)
Translating IL-6 biology into effective treatments
Ernest H. Choy et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders
QinFang Xie et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Interleukin-6: A Masterplayer in the Cytokine Network
Peter Uciechowski et al.
ONCOLOGY (2020)
Treatment of neuromyelitis optica spectrum disorders
Andrew R. Romeo et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Fc Glycan-Mediated Regulation of Placental Antibody Transfer
Madeleine F. Jennewein et al.
CELL (2019)
Fc Characteristics Mediate Selective Placental Transfer of IgG in HIV-Infected Women
David R. Martinez et al.
CELL (2019)
Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge
Nigel M. Stapleton et al.
SCIENTIFIC REPORTS (2019)
The Neonatal Fc Receptor (FcRn): A Misnomer?
Michal Pyzik et al.
FRONTIERS IN IMMUNOLOGY (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Takashi Yamamura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
Austin G. Kulasekararaj et al.
BLOOD (2019)
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Nicolas Collongues et al.
DRUGS (2019)
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Markus Reindl et al.
NATURE REVIEWS NEUROLOGY (2019)
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
S. Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder
Hiroki Masuda et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2018)
HISTORY OF MEDICINE The Myth of the Milkmaid
Arthur W. Boylston
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
Martin R. Gaudinski et al.
PLOS MEDICINE (2018)
Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment
Diana Cadena Castaneda et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6
Yuzhen Wei et al.
NEUROIMMUNOMODULATION (2018)
Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions
Ingo Kleiter et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Endothelial STAT3 Activation Increases Vascular Leakage Through Downregulating Tight Junction Proteins: Implications for Diabetic Retinopathy
Jang-Hyuk Yun et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption
Tomohiko Uchida et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption
Tomohiko Uchida et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Neuromyelitis Spectrum Disorders
Brian G. Weinshenker et al.
MAYO CLINIC PROCEEDINGS (2017)
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
Yukio Takeshita et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses
Ingo Kleiter et al.
ANNALS OF NEUROLOGY (2016)
Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
Soren B. van Witteloostuijn et al.
CHEMMEDCHEM (2016)
Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications
Roger A. Levy et al.
IMMUNOTHERAPY (2016)
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Michal Pyzik et al.
JOURNAL OF IMMUNOLOGY (2015)
The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations
Markus C. Kowarik et al.
JOURNAL OF NEUROINFLAMMATION (2015)
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Colby A. Souders et al.
MABS (2015)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Fulminant Skin GvHD With a Cytokine Pattern Resemblant of Cytokine Release Syndrome Successfully Treated With Multimodal Immunosuppression Including Tocilizumab
Yuliya Hellwig et al.
PEDIATRIC BLOOD & CANCER (2015)
The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica
Claudia F. Lucchinetti et al.
BRAIN PATHOLOGY (2014)
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
S. Jarius et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Interleukin-6 and its receptors: A highly regulated and dynamic system
Janina Wolf et al.
CYTOKINE (2014)
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
Yuan Wang et al.
JOURNAL OF DRUG TARGETING (2014)
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
Manabu Araki et al.
Modern Rheumatology (2014)
Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies
Gabriele Proetzel et al.
METHODS (2014)
Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis
Tsuyoshi Kasama et al.
RHEUMATOLOGY INTERNATIONAL (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks
Akiyuki Uzawa et al.
CLINICA CHIMICA ACTA (2013)
The Immunologic Functions of the Neonatal Fc Receptor for IgG
Timo Rath et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
Sean J. Pittock et al.
LANCET NEUROLOGY (2013)
Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
Maxime Samson et al.
ARTHRITIS AND RHEUMATISM (2012)
Functional STAT3 deficiency compromises the generation of human T follicular helper cells
Cindy S. Ma et al.
BLOOD (2012)
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2012)
CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse
Akiyuki Uzawa et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Tocilizumab Treatment Decreases Circulating Myeloid Dendritic Cells and Monocytes, 2 Components of the Myeloid Lineage
Christophe Richez et al.
JOURNAL OF RHEUMATOLOGY (2012)
Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica
Honghao Wang et al.
NEUROIMMUNOMODULATION (2012)
Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
S. Unizony et al.
ARTHRITIS CARE & RESEARCH (2012)
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Athena Chalaris et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2011)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
Kristi Baker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
EFNS guidelines on diagnosis and management of neuromyelitis optica
J. Sellner et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica Patients
Sema Icoz et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2010)
Structure and function of immunoglobulins
Harry W. Schroeder et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes
Johann Sellner et al.
JOURNAL OF AUTOIMMUNITY (2010)
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Akiyuki Uzawa et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Birth of the science of immunology
Frank C. Schmalstieg et al.
JOURNAL OF MEDICAL BIOGRAPHY (2010)
Intrathecal Pathogenic Anti-Aquaporin-4 Antibodies in Early Neuromyelitis Optica
Jeffrey L. Bennett et al.
ANNALS OF NEUROLOGY (2009)
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
N. Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Tocilizumab A Review of its Use in the Management of Rheumatoid Arthritis
Vicki Oldfield et al.
DRUGS (2009)
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis
Akiyuki Uzawa et al.
JOURNAL OF NEUROLOGY (2009)
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis
K. Yanagawa et al.
NEUROLOGY (2009)
Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes
Francisco A. Bonilla
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Advances in the understanding of the mechanism of action of IVIg
Hans-Peter Hartung
JOURNAL OF NEUROLOGY (2008)
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Shumpei Yokota et al.
LANCET (2008)
(Re)defining biopharmaceutical
Ronald A. Rader
NATURE BIOTECHNOLOGY (2008)
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
Shanu F. Roemer et al.
BRAIN (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant β2-microglobulin gene
MA Wani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases
N Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling
SJ Curnow et al.
JOURNAL OF IMMUNOLOGY (2004)
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs
DC Roopenian et al.
JOURNAL OF IMMUNOLOGY (2003)
Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling
TK Teague et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
